Holen Sie sich die Stockscreener-App
1.62
14.08%
0.20
Vorhandelsmarkt:
1.57
-0.05
-3.09%
Schlusskurs vom Vortag:
$1.42
Offen:
$1.37
24-Stunden-Volumen:
1.29M
Relative Volume:
2.74
Marktkapitalisierung:
$18.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.12M
KGV:
-1.0319
EPS:
-1.5699
Netto-Cashflow:
$-15.68M
1W Leistung:
-22.49%
1M Leistung:
-39.55%
6M Leistung:
-59.70%
1J Leistung:
-52.63%
1-Tages-Spanne:
$1.36
$1.78
1-Wochen-Bereich:
$1.11
$2.40
52-Wochen-Spanne:
$1.11
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
1.62 | 18.23M | 0 | -17.12M | -15.68M | -1.5699 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
LTRN Technical Analysis & Stock Price Forecast - Intellectia AI
Lantern Pharma (NASDAQ: LTRN) insider holds 570,000 shares, 5.1% stake - stocktitan.net
Why is Lantern Pharma stock soaring Monday? - MSN
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Stra - GuruFocus
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Lantern Pharma (LTRN) to Showcase AI Innovation in Rare Cancer R - GuruFocus
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026 - Yahoo! Finance Canada
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Foster's Daily Democrat
Fed Meeting: Whats the outlook for Lantern Pharma Incs sectorWeekly Market Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Progress Index
LTRN stock gains 18% pre-market: FDA greenlights first pediatric cancer trial for AI-driven drug - MSN
Lantern Pharma’s Dramatic Slide Reflects Key Strategic Uncertainties - timothysykes.com
Lantern Pharma Reports 2025 Financial Results - National Today
Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify - MSN
Lantern Pharma Inc. Announces Proposed Public Offering of Common Stock - issuewire.com
Lantern Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Lantern Pharma Q4 2025 slides: EPS beats as cash runway tightens - Investing.com Australia
Lantern Pharma Announces Termination of Proposed Public Offering - issuewire.com
Lantern Pharma Q4 2025 slides: EPS beats as cash runway tightens By Investing.com - Investing.com South Africa
Lantern Pharma Inc. announces plan for best-efforts public offering of common stock. - bitget.com
Lantern Pharma Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Lantern Pharma Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-03-30 - Seeking Alpha
Lantern Pharma (LTRN) Achieves Key Milestones in Oncology Develo - GuruFocus
Lantern Pharma Reports 2025 Results and Pipeline Progress - TipRanks
Lantern Pharma (LTRN) Dismisses False CEO Resignation Rumor - GuruFocus
Lantern Pharma (NASDAQ: LTRN) outlines AI-driven cancer pipeline and going concern risk - Stock Titan
Lantern Pharma (NASDAQ: LTRN) seeks equity via best‑efforts placement with warrants - stocktitan.net
Earnings call transcript: Lantern Pharma Q4 2025 sees EPS improvement, stock jumps By Investing.com - Investing.com South Africa
Earnings call transcript: Lantern Pharma Q4 2025 sees EPS improvement, stock jumps - Investing.com Australia
Lantern Pharma (NASDAQ: LTRN) trims 2025 loss as cash runway shrinks into 2026 - stocktitan.net
Q4 2025 Lantern Pharma Inc Earnings Call Transcript - GuruFocus
Lantern Pharma : Fourth Quarter 2025 Financial Results Conference Call - marketscreener.com
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - ChartMill
Dallas company secures FDA approval for pediatric cancer drug trial - The Business Journals
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - marketscreener.com
Lantern Pharma (LTRN) price target increased by 25.00% to 25.50 - MSN
Aug Volume: What are Lantern Pharma Incs recent SEC filings showingQuarterly Performance Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Lantern Pharma denies CEO departure claim, calls report false By Investing.com - Investing.com Australia
FDA clears Lantern Pharma trial for pediatric brain cancer drug By Investing.com - Investing.com Australia
Lantern Pharma confirms Panna Sharma continues to serve as president and CEO; alerts investors to false third-party report - marketscreener.com
Lantern Pharma Stock Drops as Investors Weigh Financial Results and Clinical Pipeline - timothysykes.com
Lantern Pharma Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Why Did LTRN Stock Surge 18% In Pre-Market Today? - stocktwits.com
Lantern Pharma Drops 23.9%: Bear Market Crash Shows No Immediate Signs of Recovery - Bitget
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001 - 01net
FDA Clears Lantern Pharma and Starlight Therapeutics to Begin Phase 1 Trial of STAR-001 for Pediatric CNS Cancers - geneonline.com
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.49%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):